MET and hepatocellular carcinoma: HGF (hepatocyte growth factor) reduces the antiproliferative, proapoptotic, and anti-invasive effects of lenvatinib on HCC cells with high expression of the RTK, c-Met, but does not significantly affect HCC cells with low c-Met expression.